Announcing a new article publication for Cardiovascular Innovations and Applications journal. Atrial fibrillation (AF) is a prevalent cardiac arrhythmia characterized by irregular and frequently rapid electrical activity in the atria.
Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation
Ingrezza generated $506m in revenue in Q1 2024, as per Neurocrine’s financials. Image Credit: Panchenko Vladimir / Shutterstock. The US Food and Drug Administration (FDA)